Transforming growth factor beta(TGFbeta) is a 25 kD protein which belongs to a family of ligands that regulate cell growth and differentiation. Although a number of TGFbeta binding species have been identified, the most commonly observed receptors are referred to as the type 1, type 2, and type 3 (betaglycan) TGFbeta receptor. At present, two general receptor models have been presented to account for the various cellular responses to TGFbeta. The first model proposes that all TGFbeta signaling results from the generation of a heteromeric type 1/type 2 TGFbeta receptor complex. A fundamental tenet to this model is that the type 1 TGFbeta receptor. The second model proposes that distinct TGFbeta receptor combinations mediate various aspects of TGFbeta signaling. For instance, effects of TGFbeta on extracellular matrix production and growth inhibition might result from the activation of differing receptor complexes. There is a large amount of evidence in support of both these models and it is likely that aspects of each will turn out to be t rue. In the present application two distinct approaches are proposed to address these general questions related to TGFbeta signaling. The first will use chimeric receptors consisting of the extracellular ligand binding domain of the GM-CSF alpha or beta receptor fused to the transmembrane and cytoplasmic domains of the type 1 or type 2 TGFbeta receptors. Since high affinity GM-CSF binding requires dimerization of the alpha and beta ligand binding domains, defined type 1 or type 2 TGFbeta cytoplasmic domain homodimers or heterodimers can be generated with essentially 100% specificity. Moreover, the absence of endogenous GM-CSF receptors and ability to isolate stable cell liens with equal receptor numbers and affinity provides the means to determine whether specific cellular responses are dependent upon activation of type 1/type 1 homodimers type 2/type 2 homodimers, type 1/type 2 heterodimers, and/or higher order complexes. The second approach will utilize a genetic screen to identify the signaling pathway(s) stimulated following TGFbeta receptor activation.
The specific aims to this application are: (1) determination of the TGFbeta receptor profile mediating endogenous biological and transcriptional responses; (2) determination of the effects of specific chimeric receptor complexes on downstream events dependent upon TGFbeta signaling; and (3) identification of the TGFbeta signaling pathway(s) using genetic analysis of yeast. The first two aims provide a comprehensive analysis of the receptor isoforms mediating distinct TGFbeta responses. In the third aim functional TGFbeta signaling will be reconstituted in the genetically amenable organism Saccharomyces cerevisiae. These studies have the potential to answer one of the more pressing questions in understanding TGFbeta action; that being what are the pathways activated following TGFbeta receptor activation?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM054200-03
Application #
2701748
Study Section
Human Embryology and Development Subcommittee 1 (HED)
Project Start
1996-05-01
Project End
1999-04-30
Budget Start
1998-05-01
Budget End
1999-04-30
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jung, Mi-Yeon; Kang, Jeong-Han; Hernandez, Danielle M et al. (2018) Fatty acid synthase is required for profibrotic TGF-? signaling. FASEB J 32:3803-3815
Yang, Binxia; Kilari, Sreenivasulu; Brahmbhatt, Akshaar et al. (2017) CorMatrix Wrapped Around the Adventitia of the Arteriovenous Fistula Outflow Vein Attenuates Venous Neointimal Hyperplasia. Sci Rep 7:14298
Yin, Xueqian; Kang, Jeong-Han; Andrianifahanana, Mahefatiana et al. (2017) Basolateral delivery of the type I transforming growth factor beta receptor is mediated by a dominant-acting cytoplasmic motif. Mol Biol Cell 28:2701-2711
Kang, Jeong-Han; Jung, Mi-Yeon; Yin, Xueqian et al. (2017) Cell-penetrating peptides selectively targeting SMAD3 inhibit profibrotic TGF-? signaling. J Clin Invest 127:2541-2554
Yang, Binxia; Brahmbhatt, Akshaar; Nieves Torres, Evelyn et al. (2016) Tracking and Therapeutic Value of Human Adipose Tissue-derived Mesenchymal Stem Cell Transplantation in Reducing Venous Neointimal Hyperplasia Associated with Arteriovenous Fistula. Radiology 279:513-22
Janardhanan, Rajiv; Yang, Binxia; Kilari, Sreenivasulu et al. (2016) The Role of Repeat Administration of Adventitial Delivery of Lentivirus-shRNA-Vegf-A in Arteriovenous Fistula to Prevent Venous Stenosis Formation. J Vasc Interv Radiol 27:576-83
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Andrianifahanana, Mahefatiana; Hernandez, Danielle M; Yin, Xueqian et al. (2016) Profibrotic up-regulation of glucose transporter 1 by TGF-? involves activation of MEK and mammalian target of rapamycin complex 2 pathways. FASEB J 30:3733-3744
Wilkes, Mark C; Repellin, Claire E; Kang, Jeong-Han et al. (2015) Sorting nexin 9 differentiates ligand-activated Smad3 from Smad2 for nuclear import and transforming growth factor ? signaling. Mol Biol Cell 26:3879-91
Nallet-Staub, Flore; Yin, Xueqian; Gilbert, Cristèle et al. (2015) Cell density sensing alters TGF-? signaling in a cell-type-specific manner, independent from Hippo pathway activation. Dev Cell 32:640-51

Showing the most recent 10 out of 46 publications